UNSPSC 51273018: Diperodon hydrochloride

This classification denotes an anesthetic agent with the molecular formula C22H27N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5YZ5R8I73Y, chemically known as 1,2-propanediol, 3-piperidino-, dicarbanilate, hydrochloride but more generally known as diperodon hydrochloride, which bears US NIH Compound Identifier 10830. European Medicines Agency schedules Diperodon hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13620MIG.

Most nations, for tariff and trade purposes, schedule diperodon hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, DIPERODON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Diperodon hydrochloride bears US NLM identifiers UMLS ID C0521935 and NCI Concept Code C75091. SMILES: C1CCC(CC1)NC(=O)OCC(CN2CCCCC2)OC(=O)NC3CCCCC3.CL.

UNSPSC 51273018 Diperodon hydrochloride is a Commodity code that does not reflect the work currently being solicited under it in recent state and local opportunities. The three recent solicitations tagged to this code cover naloxone procurement, a direct-to-manufacturer prescription program initiative, and a multistate cooperative purchasing agreement for generic pharmaceuticals and over-the-counter products — none of which involve diperodon hydrochloride. The mismatch suggests either a classification error in the source data or that this specific pharmaceutical is rarely procured through open state and local bidding. No opportunities specifically soliciting diperodon hydrochloride appear in the recent record.

The issuing bodies for the related pharmaceutical procurements include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). Recent activity spans Florida, Texas, and Minnesota, with MMCAP participation extending to Oregon. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered vendor capabilities for direct manufacturer relationships supporting prescription fulfillment; and MMCAP's RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026.